Drug Approval | November 10, 2025
Johnson & Johnson gets FDA nod for new depression treatment
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies now has 29 active product approvals in Vietnam alone
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
The said inspection concluded with Zero Form 483 observation
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Sumatriptan injection is indicated in adults for the acute treatment of migraine
Subscribe To Our Newsletter & Stay Updated
